Australia - Kiingereza - APVMA (Australian Pesticides and Veterinary Medicines Authority)

basf australia ltd. - glufosinate-ammonium - aqueous concentrate - glufosinate-ammonium organophosphorus-phosphinic ac active 200.0 g/l - herbicide - canola - invigor hybrid varieties | invigor hybrid canola varieties - seed p | canola:2 leaf to early bolting | seed production - annual ryegrass | annual ryegrass - suppression | barley grass | brome grass | canola - non-tolerant plants | capeweed | corn gromwell, ironweed or sheepweed | crassula | fumitory | loosestrife | lupins | medic | prickly lettuce | scotch thistle | silvergrass - vulpia spp. | subterranean clover | three cornered jack or doublegee | toad rush | tree hogweed | vetches | volunteer barley | volunteer chickpea | volunteer field pea | volunteer lentil | volunteer oat | volunteer wheat | wild oat | wireweed or knotweed - seed | yellow burrweed - amsinckia intermedia | annual medic | bromus diandrus | bromus rigidus | buglossiodes arvense | burr medic | common oats | cotton thistle | fallopia patulum | field pea | h. hexastichon | hairy vetch | heraldic thistle | hogweed | lentil | lysimachia spp. | narrowleaf vetch | pink weed | rigid ryegrass | silver grass | slender vetch | spiny emex | spurred vetch | squarestem vetch | stonecrop | triticum aestivum | true scotch thistle | vetch | vicia angustifolia | vicia hirsut

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

amneal pharma europe limited - bupivacaine hydrochloride - solution for injection - 5.0 mg/ml

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

amneal pharma europe limited - bupivacaine hydrochloride - solution for injection - 2.5 mg/ml

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

amneal pharma europe limited - ciprofloxacin lactate - solution for infusion - 2 mg/ml

Filipino - Kiingereza - FDA (Food And Drug Administration)

amn life science private limited - india; importer: biocare lifesciences, inc.; distributor: the cathay drug co. inc. - cefuroxime axetil - granules for oral suspension - 125mg / 5 ml

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - cefazolin sodium, quantity: 2096 mg - injection, powder for - excipient ingredients: - cefazolin is indicated in the treatment of the following serious infections due to susceptible organisms:,respiratory tract infections due to s. pneumoniae, klebsiella species, h. influenzae, staph. aureus (penicillin-sensitive and penicillin- resistant), and group a beta-haemolytic streptococci.,injectable benzathine penicillin is considered to be the drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever.,cefazolin is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available at present.,genitourinary tract infections due to esch. coli, pr. mirabilis, klebsiella species, and some strains of enterobacter and enterococci.,skin and skin structure infections due to staph. aureus (penicillin-sensitive and penicillin- resistant), and group a beta-haemolytic streptococci and other strains of streptococci.,bone and joint infections due to staph. aureus.,septicaemia due to s. pneumoniae, staph. aureus (penicillin-sensitive and penicillin-resistant), pr. mirabilis, esch. coli and klebsiella species.,endocarditis due to staph. aureus (penicillin-sensitive and penicillin-resistant), and group a beta-haemolytic streptococci.,appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - cefazolin sodium, quantity: 2096 mg - injection, powder for - excipient ingredients: - cefazolin is indicated in the treatment of the following serious infections due to susceptible organisms:,respiratory tract infections due to s. pneumoniae, klebsiella species, h. influenzae, staph. aureus (penicillin-sensitive and penicillin- resistant), and group a beta-haemolytic streptococci.,injectable benzathine penicillin is considered to be the drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever.,cefazolin is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available at present.,genitourinary tract infections due to esch. coli, pr. mirabilis, klebsiella species, and some strains of enterobacter and enterococci.,skin and skin structure infections due to staph. aureus (penicillin-sensitive and penicillin- resistant), and group a beta-haemolytic streptococci and other strains of streptococci.,bone and joint infections due to staph. aureus.,septicaemia due to s. pneumoniae, staph. aureus (penicillin-sensitive and penicillin-resistant), pr. mirabilis, esch. coli and klebsiella species.,endocarditis due to staph. aureus (penicillin-sensitive and penicillin-resistant), and group a beta-haemolytic streptococci.,appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - cefazolin sodium, quantity: 1048 mg - injection, powder for - excipient ingredients: - cefazolin is indicated in the treatment of the following serious infections due to susceptible organisms:,respiratory tract infections due to s. pneumoniae, klebsiella species, h. influenzae, staph. aureus (penicillin-sensitive and penicillin- resistant), and group a beta-haemolytic streptococci.,injectable benzathine penicillin is considered to be the drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever.,cefazolin is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available at present.,genitourinary tract infections due to esch. coli, pr. mirabilis, klebsiella species, and some strains of enterobacter and enterococci.,skin and skin structure infections due to staph. aureus (penicillin-sensitive and penicillin- resistant), and group a beta-haemolytic streptococci and other strains of streptococci.,bone and joint infections due to staph. aureus.,septicaemia due to s. pneumoniae, staph. aureus (penicillin-sensitive and penicillin-resistant), pr. mirabilis, esch. coli and klebsiella species.,endocarditis due to staph. aureus (penicillin-sensitive and penicillin-resistant), and group a beta-haemolytic streptococci.,appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - cefazolin sodium, quantity: 524 mg - injection, powder for - excipient ingredients: - cefazolin is indicated in the treatment of the following serious infections due to susceptible organisms:,respiratory tract infections due to s. pneumoniae, klebsiella species, h. influenzae, staph. aureus (penicillin-sensitive and penicillin- resistant), and group a beta-haemolytic streptococci.,injectable benzathine penicillin is considered to be the drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever.,cefazolin is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available at present.,genitourinary tract infections due to esch. coli, pr. mirabilis, klebsiella species, and some strains of enterobacter and enterococci.,skin and skin structure infections due to staph. aureus (penicillin-sensitive and penicillin- resistant), and group a beta-haemolytic streptococci and other strains of streptococci.,bone and joint infections due to staph. aureus.,septicaemia due to s. pneumoniae, staph. aureus (penicillin-sensitive and penicillin-resistant), pr. mirabilis, esch. coli and klebsiella species.,endocarditis due to staph. aureus (penicillin-sensitive and penicillin-resistant), and group a beta-haemolytic streptococci.,appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - cefazolin sodium, quantity: 1048 mg - injection, powder for - excipient ingredients: - cefazolin is indicated in the treatment of the following serious infections due to susceptible organisms:,respiratory tract infections due to s. pneumoniae, klebsiella species, h. influenzae, staph. aureus (penicillin-sensitive and penicillin- resistant), and group a beta-haemolytic streptococci.,injectable benzathine penicillin is considered to be the drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever.,cefazolin is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available at present.,genitourinary tract infections due to esch. coli, pr. mirabilis, klebsiella species, and some strains of enterobacter and enterococci.,skin and skin structure infections due to staph. aureus (penicillin-sensitive and penicillin- resistant), and group a beta-haemolytic streptococci and other strains of streptococci.,bone and joint infections due to staph. aureus.,septicaemia due to s. pneumoniae, staph. aureus (penicillin-sensitive and penicillin-resistant), pr. mirabilis, esch. coli and klebsiella species.,endocarditis due to staph. aureus (penicillin-sensitive and penicillin-resistant), and group a beta-haemolytic streptococci.,appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin.